SPECIALITY pharmaceutical company Alliance Pharma has awarded a commercial supply contract for three of its products to North-East based sterile manufacturing expert SCM Pharma, a development and contract manufacturing organisation (CDMO).

SCM Pharma will look after the filling, packaging and testing of three injectable products on behalf of Alliance Pharma.

The products include Edrophonium, which is supplied in terminally sterilised ampoules and used in the diagnosis of myasthenia gravis, an autoimmune disease leading to fluctuating muscle weakness and fatigability.

The products also include the organic compound Isoniazid, which is supplied as a terminally sterilised ampoule and used as a first-line antituberculosis product in prevention and treatment.

The third product is Pentagastrin, which will be aseptically filled into ampoules using isolator technology at SCM Pharma's MHRA-licensed UK-based facility. The pentagastrin-stimulated calcitonin test is a diagnostic test for medullary carcinoma of the thyroid.

David Yau, production, technical & quality director at Alliance Pharma, said: "We were impressed by SCM Pharma's track record and are confident in their ability to deliver these three products."

All three drugs are established yet niche products, which fit well with the CDMO's ability to support speciality pharmaceutical businesses with the supply of niche and often lower volume licensed products.

SCM Pharma, which is also heavily involved with clinical manufacturing, commands a distinctive position in the global contract drug manufacturing market with its ability to sterile fill finish C-14 radiolabeled and potent products such as cytotoxics to cGMP manufacturing standards.

The contract filling specialist offers sterile services to pharma companies across the world and has specific expertise in the vial, syringe and ampoule filling of liquids, gels and powders.

Graham Dotchin, commercial director at SCM Pharma, said: "We are delighted to be working with the team at Alliance Pharma and supporting them in the supply of these three sterile products.

"The range of contract filling required across the projects underlines our flexibility to meet client needs and capability of terminally sterilising and aseptically processing drug products for clinical trials and commercial supply.

"We hope this is the start of a long term relationship with Alliance Pharma and look forward to meeting their product supply requirements."

Along with a client portfolio featuring several specialty pharmaceutical companies, SCM Pharma has now worked with a third of top ten big pharma on various product indications across a number of therapeutic areas including cancer and diabetes.

For more information:

Raman Sehgal
SCM Pharma
01661 838 186
[email protected]

Suggested Articles

While the failure might be a missed chance at revenue, it shouldn’t hurt Ibrance’s ability to rack up sales in the metastatic setting, one exec says.

Patients receiving Bavencio actually did worse than those who got placebo, increasing the risk of death by 31%.

Seattle Genetics and Astellas’ newcomer Padcev now has what every cancer drugmaker is looking for: Randomized trial data showing it can extend lives.